The Health Economics of Bladder Cancer

Botteman, Marc; Pashos, Chris L.; Redaelli, Alberto; Laskin, Benjamin L.; Hauser, Robert

doi:10.2165/00019053-200321180-00003

Cited by 141 publications

(50 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The highest incidence is reported in North America and Western Europe and the lowest in China, Japan, Korea and central Africa [1,2]. Up to 85% of cases of urinary bladder cancer are confined to the mucosa (stage Ta and carcinoma in situ, CIS) or submucosa (stage T1) on first diagnosis [3]. Approximately 70% of patients with non-muscle-invasive bladder cancer (NMIBC) present as pTa, 20% as pT1 and 10% as CIS lesions [4].…”

Section: Introductionmentioning

confidence: 99%

Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables

et al. 2012

View full text Add to dashboard Cite

Objectives: It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables. Patients and Methods: Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated. Results: The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups. Conclusion: From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Because of long-term survival and the need for lifelong routine monitoring and treatment, the cost per patient with bladder cancer from diagnosis to death is highest of all cancers [2]. The majority (70%) of bladder cancers are non-muscle invasive (stage pTa, pT1 and carcinoma in situ) [3].…”

Section: Introductionmentioning

confidence: 99%

Multiprobe Fluorescence in situ Hybridization (UroVysion) for the Detection of Urothelial Carcinoma – FISHing for the Right Catch

Bubendorf¹

2011

Acta Cytologica

View full text Add to dashboard Cite

Urinary cytology has a well-established role in the detection and monitoring of urothelial carcinoma. The main strength of cytology is the high specificity for high-grade urothelial carcinoma and carcinoma in situ, but it has a low sensitivity for low-grade, non-invasive tumors. There are several other limitations of cytology. Cytology of the upper urinary tract and after intravesical therapy with bacillus Calmette-Guerin is notoriously difficult to interpret. In addition, there is a poorly defined but commonly used category of atypical cytology of uncertain significance. The UroVysion multiprobe fluorescence in situ hybridization has emerged as a helpful tool to address these limitations. It consists of fluorescently labeled DNA probes to detect increased copy numbers (polysomy) of the chromosomes 3, 7 and 17 and deletion of 9p21, the site of the P16 tumor suppressor gene. Multiple studies have shown that fluorescence in situ hybridization in voided urine and washing specimens can help in patient management due to its superior sensitivity over cytology in different situations. It can be particularly useful to clarify equivocal cytological findings. However, some aspects remain to be further addressed including cost efficiency, optimal cut-off values and the true performance under real-life conditions.

show abstract

“…Bladder cancer is one of the 10 commonest cancers worldwide and treatment costs are substantial [1]. Only a few authors [2] have studied the economic aspects of bladder cancer treatment. Because of long-term survival and the need for lifelong routine monitoring and treatment the cost per bladder cancer patient from diagnosis to death is the highest among all cancers [2].…”

Section: Introductionmentioning

confidence: 99%